<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01806792</url>
  </required_header>
  <id_info>
    <org_study_id>HL_RSNPM_301</org_study_id>
    <nct_id>NCT01806792</nct_id>
  </id_info>
  <brief_title>Post-menopausal Women Osteoporosis(Phase III)</brief_title>
  <official_title>For 4 Months, the Multi Center, Double Blinded, Randomized, Active Controlled, Comparative Clinical Study to Assess the Efficacy and the Safety to Improvement Effect of Vit.D of Risenex Plus M Tablet in Patients With In Post-menopausal Women Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and the safety of Risedronate,
      cholecalciferol combination tablet in patients with Osteoporosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the efficacy and the safety of Monthly Risedronate
      with cholecalciferol on 25 Hydroxyvitamin D level and bone markers patients with
      osteoporosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients with 25(OH)D level &lt; 20 ng/mL at 16 weeks.</measure>
    <time_frame>16 weeks form first drug adminstration.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with 25(OH)D level &lt; 9 ng/mL at 16 weeks, change of 25(OH)D level and Bone Markers.</measure>
    <time_frame>16 weeks form first drug administration.</time_frame>
    <description>Secondary end point is :
proportion of patients with 25(OH)D level &lt; 9 ng/mL at 16 weeks
change of 25(OH)D level
change of BSAP
change of CTX
change of Ca
change of phosphorous
change of PTH
change of 8-foot walking test, Sit-To-Stand test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Postmenopausal Women Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Risendronate and Cholecalciferol combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>risedronate 150mg and cholecalciferol 30,000 IU 1 tablet + Placebo(for risedronate 150mg) 1 tablet by once a month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risedronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>risedronate 150mg 1 tablet + Placebo(for risedronate 150mg and cholecalciferol 30,000 IU) 1 tablet by once a month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risedronate combine</intervention_name>
    <arm_group_label>Risendronate and Cholecalciferol combination</arm_group_label>
    <other_name>- Other name : Risenex M(risedronate 150mg and cholecalciferol 30,000 IU combined)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risedronate</intervention_name>
    <arm_group_label>Risedronate</arm_group_label>
    <other_name>Other name : Actonel(Risedronate 150mg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo(for Risedronate)</intervention_name>
    <arm_group_label>Risendronate and Cholecalciferol combination</arm_group_label>
    <other_name>once a month</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo(for risedronate combine)</intervention_name>
    <arm_group_label>Risedronate</arm_group_label>
    <other_name>once a month</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. women osteoporosis

          2. patients with a diagnosis of Postmenopausal over 6 Months if they had a bone mineral
             density T-score of &lt; -2.5 at the mean lumbar spine (L1-4), femoral neck, or total, or
             a T-score of &lt; -1.0 with radiologic evidence of at least one vertebral fracture.
             Menopause was defined as no natural menses for at least 1 year and a serum FSH level &gt;
             40 IU/L, with a reported hysterectomy

          3. low levels of 25(OH)D &gt; 9 ng/mL

          4. patients who give written consent of agreement to voluntarily participate in the
             clinical study

          5. patients who can read and understand written instructions

        Exclusion Criteria:

          1. patients who had contraindications to oral bisphosphonates, such as esophageal
             strictures

          2. ALT, AST ≥ 2×UNL and Serum Creatinine ≥ 1.5×UNL

          3. low levels of 25(OH)D (less than 9 ng/mL).

          4. Previous use of oral bisphosphonates and vitamin D were allowed, but a washout period
             was needed, depending on the duration of treatment. Two-year washout periods were
             needed for bisphosphonate users and 3-6-month periods were required for vitamin D
             users of &gt; 200 IU.

          5. drug administration after diagnosing as alcoholic or psychical disease

          6. patients whom the investigators judge as improper to participate in this clinical
             trial 7)13.patients who have experience to participate in other clinical trial within
             30 days prior to study participation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyoung-Moo Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chung-ang university hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2013</study_first_submitted>
  <study_first_submitted_qc>March 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2013</study_first_posted>
  <last_update_submitted>March 6, 2013</last_update_submitted>
  <last_update_submitted_qc>March 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Risedronate Sodium</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

